OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Release Date
2025
(2)
2021
(2)
2026
(1)
2022
(1)
2019
(1)
2017
(1)
2015
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study.
Not available
S-EPMC9038712
|
biostudies-literature
Cite
Comprehensive transcriptomic analysis reveals canonical and novel pathways modulated by nanoceria in mammalian retinal degeneration.
Not available
S-EPMC12852738
|
biostudies-literature
Cite
Lamin A/C regulates cerebellar granule cell maturation.
Not available
S-EPMC11972193
|
biostudies-literature
Cite
Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.
Not available
S-EPMC4515982
|
biostudies-literature
Cite
Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin system.
Not available
S-EPMC6561907
|
biostudies-literature
Cite
Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis.
Not available
S-EPMC8353748
|
biostudies-literature
Cite
Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.
Not available
S-EPMC5664299
|
biostudies-literature
Cite
Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa-Carbidopa Intestinal Gel: A Nation-Wide, Multicenter, Longitudinal, "Real-World" Study. The EPIC Study.
Not available
S-EPMC12260476
|
biostudies-literature
Cite
Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology.
Not available
S-EPMC8648564
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets